Profound Medical Corp. (PROF) shares declined 6% during early Friday trading. The company anticipates revenue growth of 70%-75% for 2025, primarily driven by advancements in its TULSA-AI technology and progress from the CAPTAIN trial. The company reported second-quarter revenue of $2.2 million and is currently focused on expanding its TULSA-PRO product line.
Profound Medical Corp. expects cancer associations to publish new guidelines, which should enhance market recognition of its TULSA technology.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments